stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Current ratio
Organon & Co.'s current ratio at the end of the quarter to 30 September 2026 was 2.0×, up 0.2× from fiscal 2025 (1.8×). Over the past ten years it has ranged from 1.3× (fiscal 2020) to 2.9× (fiscal 2019); the current reading is higher than 75% of that period. That is above the Drug Manufacturers General industry median of 1.4× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.8× | 13.83% |
| FY2024 | 1.6× | 3.55% |
| FY2023 | 1.5× | (1.28%) |
| FY2022 | 1.6× | 8.09% |
| FY2021 | 1.4× | 8.49% |
| FY2020 | 1.3× | (54.75%) |
| FY2019 | 2.9× | 22.69% |
| FY2018 | 2.4× | — |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 2.0× | 3.62% |
| Jun 2026 | 2.0× | (0.97%) |
| Mar 2026 | 2.0× | 8.34% |
| Dec 2025 | 1.8× | 3.79% |
| 21 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| AMRN Amarin Corporation PLC compare | 3.5× |
| GRFS Grifols, S.A. compare | 2.3× |
| OGN Organon & Co. | 2.0× |
| BIIB Biogen Inc. compare | 1.9× |
| BMY Bristol Myers Squibb Company compare | 1.6× |
| PFE Pfizer Inc. compare | 1.4× |
| SNY Sanofi compare | 1.1× |
| GSK GSK PLC Sponsored ADR compare | 0.9× |
| NVO Novo Nordisk A/S compare | 0.8× |
| Drug Manufacturers General industry median | 1.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement